glp-1 supply news november 2025 Weight Loss Drug Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap semaglutide supply news november 2025

Similar content being viewed by others Introduction Diabetes and depression are global health problems with a rising prevalence, affecting 10.5 and 5% of the world population, respectively [1, 2]

Mazdutide needs longer-term data at higher doses to demonstrate comparable sustainability

12 mg dose group : Mean weight reduction of approximately 24.2% the highest recorded in the trial

Mozafarrian D et al

doi: 10.3389/fphar.2023.1303844 Received 28 September 2023 Accepted 30 November 2023 Published 11 December 2023 Volume 14 - 2023 Edited by Alessio Squassina, University of Cagliari, Italy Reviewed by Michele Mazzanti, University of Milan, Italy Yashmin Choudhury, Assam University, India Updates Copyright 2023 Greco, Coperchini, Croce, Magri, Teliti and Rotondi

There is no scientific evidence supporting the effectiveness of these supplements for weight loss or blood sugar management." Kumar adds that GLP-1 supplements are "largely a marketing ploy to capitalize on the current cultural craze around weight loss medications." If they do have an effect, it's likely mild and "not effective enough to treat overweight and obesity," she explains